 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Provention Bio (NASDAQ:PRVB Get Rating) and Avalo Therapeutics (NASDAQ:AVTX Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ...

Contrasting Provention Bio (NASDAQ:PRVB) & Avalo Therapeutics (NASDAQ:AVTX)

Provention Bio (NASDAQ:PRVB  Get Rating) and Avalo Therapeutics (NASDAQ:AVTX  Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations...

Provention Bio, Inc. (NASDAQ:PRVB Get Rating) shares reached a new 52-week high on Wednesday . The stock traded as high as $24.99 and last traded at $24.99, with a volume of 2360526 shares changing hands. The stock had previously closed at $24.23. Wall Street Analysts Forecast Growth Several ...

Provention Bio (NASDAQ:PRVB) Reaches New 12-Month High at $24.99

Provention Bio, Inc. (NASDAQ:PRVB  Get Rating) shares reached a new 52-week high on Wednesday . The stock traded as high as $24.99 and last traded at $24.99, with a volume of 2360526 shares changing hands. The stock had previously closed at $24.23. Wall Street Analysts Forecast Growth Several...

This price move could be a signal that PRVB may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Provention Bio (PRVB, $24.98) price may drop as it broke higher Bollinger Band on Apr 26, 2023

This indicator may be signaling PRVB's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Provention Bio (PRVB, $24.98) entered Uptrend as Momentum indicator ascends above 0 level on Apr 26, 2023

This is a signal that PRVB's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Provention Bio (PRVB, $24.98) RSI Indicator left the overbought zone on April 26, 2023

Hart-Scott-Rodino waiting period expires for Sanofis acquisition of Provention Bio, Inc. Paris, France April 26, 2023 Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act), applicable to Sanofis proposed acquisition of...

Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

This indicator may be signaling that PRVB's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Provention Bio (PRVB, $24.4) entered Downtrend as Momentum indicator drops below 0 level on Apr 24, 2023

Over the last three days, A.I.dvisor has detected that PRVB's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For ...

Provention Bio (PRVB, $24.32) Aroon Indicator entered an Uptrend on April 21, 2023.

Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses.  Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.

Watchers	7,717
52-Wk Low	$3.19
52-Wk High	$25.00

Market Cap	$2.37B
Volume (M)	9.12M
52-Wk High	$25.00
52-Wk Low	$3.19

PRVB Provention Bio Inc

About

Feed

News

Fundamentals